Localized Scleroderma: A Clinical Review

Area of Science:

• Dermatology
• Rheumatology
• Pediatric Rheumatology

Background:

• Localized scleroderma (LS) is a fibrotic condition characterized by excessive collagen deposition.
• It primarily affects the skin, subcutaneous tissue, or both, leading to tissue thickening.
• The main challenges for untreated patients are deformities and growth defects, not increased mortality.

Purpose of the Study:

• To summarize the current understanding of localized scleroderma.
• To outline current treatment strategies, particularly pharmacologic options.
• To identify the need for further research into optimal treatment regimens.

Main Methods:

• Review of existing literature on localized scleroderma.
• Analysis of current pharmacologic treatment approaches.
• Identification of knowledge gaps regarding treatment duration and dosage.

Main Results:

• Treatment is individualized based on lesion type and stage.
• The combination of methotrexate and systemic glucocorticoids is the current standard pharmacologic therapy.
• Controlled trials are lacking to establish optimal treatment length and maintenance doses.

Conclusions:

• Localized scleroderma poses significant risks of deformity and growth abnormalities.
• Methotrexate plus systemic glucocorticoids is the established first-line treatment.
• Further controlled trials are essential to define optimal treatment protocols for LS.